Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

211.93 +0.55 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,042,556
Open 211.38
Bid (Size) 207.11 (1)
Ask (Size) 215.00 (1)
Prev. Close 211.38
Today's Range 207.19 - 212.71
52wk Range 187.16 - 372.12
Shares Outstanding 147,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
From Happify Health
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga

Performance

YTD
-13.19%
-13.19%
1 Month
+4.73%
+4.73%
3 Month
+0.46%
+0.46%
6 Month
-9.51%
-9.51%
1 Year
-39.30%
-39.30%

More News

Read More
Why Scholar Rock Shares Are Trading Higher Today
Via Benzinga
Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover?
Via Investor's Business Daily
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Via Benzinga
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
Via Benzinga
NASDAQ:BIIB Long Term Investor Alert: Investigation of Potential Wrongdoing at Biogen Inc.
Via SBWire
Analyzing Biogen's Short Interest
Via Benzinga
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
7 No-Brainer Biotech Stocks to Add to Your Buy List
Via InvestorPlace
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Via FinancialNewsMedia
Exposures COVID-19
Quant Ratings Updated on 66 Stocks
Via InvestorPlace
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
Via Investor's Business Daily
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much
Via Benzinga
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Via InvestorPlace
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 23
Via Benzinga
Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm
Via Benzinga
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Via Benzinga
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
Via Investor's Business Daily
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
From MedRhythms
Via Business Wire
Looking Into Biogen's Return On Capital Employed
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.